CellRapeutics™ CAR-T Therapy Development Services in the Non-Cancer Field

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CART Therapy Development for Non-cancer Diseases

While Chimeric Antigen Receptor (CAR) T cell therapy has experienced immense success in treating cancer, the potential for expanding its application into non-cancer fields has garnered significant interest. Creative Biolabs has carried out a series of related developments for non-cancer disease types that can be targeted by CART therapy, providing customers with development services for a variety of non-cancer disease types of CART cell therapy, and helping customers achieve early success in their projects.

Our CellRapeutics™ CART Therapy Development Services in the Non-cancer Field

With over 20 years of expertise in the biological field, our team combines scientific acumen with technical proficiency to deliver unparalleled solutions. Creative Biolabs offers a comprehensive suite of CART Therapy Development Services tailored specifically for non-cancer indications. Our multidisciplinary team of experts specializes in customizing CAR constructs, optimizing manufacturing processes, and conducting preclinical studies to evaluate the efficacy and safety of CART therapy in diverse disease models. From autoimmune disorders like lupus and myasthenia gravis to metabolic conditions such as Type 1 diabetes and congenital hyperinsulinism, our CART Therapy Development Services are designed to address the unmet medical needs of patients suffering from a wide range of non-cancer diseases.

We provide the following featured services for customers' reference:

Published Data of CART Therapy Development in the Non-cancer Field

The efficacy of CART therapy in non-cancer applications is underscored by a wealth of published data.

CART Therapy in Age-related Metabolic Dysfunction

CAR T cells offer a different approach by redirecting T cell specificity towards cells expressing specific cell-surface antigens. CAR T cells, as "living drugs", have the potential for long-lasting effects with a single administration and the ability to target antigens specifically expressed on target cells. Researchers discussed in the content involve uPAR-targeting CAR T strategy, which can efficiently eliminate the senescent cells in young animals and reverse of liver fibrosis.

Fig.1 uPAR CAR-T cells block age-associated phenotypes. (Amor, et al., 2024) Fig.1 Anti-uPAR CAR-T cells block the natural age-associated phenotypes.¹

CART Therapy in Diabetes

In addressing T1D using CAR T cell therapy, researchers have developed several CART-related strategies. The first involves targeting and eliminating the autoimmune cells responsible for beta cell destruction. In addition, the development of a novel biomimetic five-module chimeric antigen receptor (5MCAR) targeting autoimmune CD4+ T cells has demonstrated efficacy in preventing and treating T1D, with long-term persistence observed in some subjects. Furthermore, another avenue of exploration in T1D treatment with CAR T cell therapy involves the utilization of regulatory T cells (Tregs) to dampen immune responses in autoimmune conditions.

Fig.2 CAR-T strategies for diabetes. (Aghajanian, et al., 2022) Fig.2 CAR-T strategies for the treatment of diabetes.²

With a focus on innovation, precision, and efficacy, Creative Biolabs continues to drive progress in non-cancer CART Therapy applications. If you have any inquiry requirements about our CellRapeutics™ CART therapy development services in the non-cancer field, please contact our tech team to learn more.

References

Amor, Corina, et al. "Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction." Nature Aging (2024): 1-14.
Aghajanian, Haig, Joel G. Rurik, and Jonathan A. Epstein. "CAR-based therapies: opportunities for immuno-medicine beyond cancer." Nature metabolism 4.2 (2022): 163-169.